Novo Nordisk (NVO) said Thursday that the US Food and Drug Administration has approved Alhemo (concizumab-mtci) as a once-daily prophylaxis to prevent or reduce the frequency of bleeding in adults and children above 12 years with hemophilia A or B without inhibitors.
The approval is based on the results of a phase 3 trial which showed that Alhemo cut the annualized bleeding rate by 79% in hemophilia B patients and by 86% in hemophilia A patients compared with no prophylaxis, the company said.
The approval offers patients in this population a subcutaneous injection option expanding on the drug's earlier approval in December 2024 for use in patients with hemophilia A or B with inhibitors, Novo Nordisk said.
Shares of Novo Nordisk were up 2% in early Friday trading.
Price: 48.10, Change: +1.03, Percent Change: +2.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.